Drug Profile
Research programme: NOX inhibitors - GenKyoTex
Alternative Names: GKT-03; GKT-136901; GKT-771; GKT-901; HTS programme; NOX inhibitors - GenKyoTexLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator GenKyoTex
- Class Analgesics; Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action NOX1 protein inhibitors; NOX4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; Hearing loss; Inflammation; Pain; Parkinson's disease
- Discontinued Diabetic nephropathies; Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Switzerland
- 28 Nov 2021 No recent reports of development identified for research development in Parkinson's-disease in France
- 28 Jun 2021 No recent reports of development identified for preclinical development in Inflammation in Switzerland